MA34939B1 - Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation - Google Patents

Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Info

Publication number
MA34939B1
MA34939B1 MA35350A MA35350A MA34939B1 MA 34939 B1 MA34939 B1 MA 34939B1 MA 35350 A MA35350 A MA 35350A MA 35350 A MA35350 A MA 35350A MA 34939 B1 MA34939 B1 MA 34939B1
Authority
MA
Morocco
Prior art keywords
diseases
prevention
treatment
heterocyclylbenzyl
pyrazoles
Prior art date
Application number
MA35350A
Other languages
English (en)
French (fr)
Inventor
Michael Härter
Hartmut Beck
Susanne Greschat-Schade
Peter Ellinghaus
Kerstin Unterschemman
Joachim Schuhmacher
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34939(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34939B1 publication Critical patent/MA34939B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA35350A 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation MA34939B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08
PCT/EP2011/057021 WO2011141326A1 (de) 2010-05-08 2011-05-03 Substituierte heterocyclylbenzyl-pyrazole und ihre verwendung

Publications (1)

Publication Number Publication Date
MA34939B1 true MA34939B1 (fr) 2014-03-01

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35350A MA34939B1 (fr) 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Country Status (26)

Country Link
US (2) US20130172311A1 (https=)
EP (1) EP2569312B1 (https=)
JP (1) JP5727002B2 (https=)
KR (1) KR20130108997A (https=)
CN (1) CN103003269B (https=)
AR (1) AR081368A1 (https=)
AU (1) AU2011252223A1 (https=)
BR (1) BR112012028651A2 (https=)
CA (1) CA2798375A1 (https=)
CO (1) CO6640218A2 (https=)
CR (1) CR20120570A (https=)
CU (1) CU20120157A7 (https=)
DO (1) DOP2012000284A (https=)
EA (1) EA201291167A1 (https=)
EC (1) ECSP12012288A (https=)
ES (1) ES2462522T3 (https=)
IL (1) IL222851A0 (https=)
MA (1) MA34939B1 (https=)
MX (1) MX2012012960A (https=)
PE (1) PE20130228A1 (https=)
PH (1) PH12012502202A1 (https=)
SG (1) SG185459A1 (https=)
TN (1) TN2012000531A1 (https=)
TW (1) TW201200510A (https=)
UY (1) UY33369A (https=)
WO (1) WO2011141326A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685875C (en) * 2007-05-01 2015-10-06 Hill's Pet Nutrition, Inc. Methods and compositions for diagnosing osteoarthritis in a feline
CA2687306A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20130228A1 (es) * 2010-05-08 2013-03-15 Bayer Ip Gmbh Heterociclilbencilpirazoles sustituidos
EP2867230B1 (en) 2012-07-02 2020-02-12 Monsanto Technology LLC Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
EP2888253A4 (en) * 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
ES2691643T3 (es) 2012-08-24 2018-11-28 Board Of Regents, The University Of Texas System Moduladores heterocíclicos de la actividad de HIF para el tratamiento de enfermedades
WO2015130790A2 (en) 2014-02-25 2015-09-03 Board Of Regents, University Of Texas System Salts of heterocyclic modulators of hif activity for treatment of disease
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
KR102544307B1 (ko) * 2017-01-13 2023-06-15 닛산 가가쿠 가부시키가이샤 방향족 디아민 화합물 전구체의 제조 방법
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用
WO2025096662A1 (en) * 2023-10-30 2025-05-08 Pretzel Therapeutics, Inc. Compositions and inhibitors of polrmt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
CA2687306A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
AU2009316019A1 (en) * 2008-11-14 2010-05-20 Bayer Intellectual Property Gmbh Heterocyclically substituted aryl compounds as HIF inhibitors
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
WO2010054764A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
PE20130228A1 (es) * 2010-05-08 2013-03-15 Bayer Ip Gmbh Heterociclilbencilpirazoles sustituidos

Also Published As

Publication number Publication date
US20120028950A1 (en) 2012-02-02
US8470811B2 (en) 2013-06-25
CU20120157A7 (es) 2013-03-27
CA2798375A1 (en) 2011-11-17
CN103003269B (zh) 2015-11-25
PE20130228A1 (es) 2013-03-15
JP2013526497A (ja) 2013-06-24
PH12012502202A1 (en) 2013-02-04
SG185459A1 (en) 2012-12-28
KR20130108997A (ko) 2013-10-07
EP2569312B1 (de) 2014-03-26
MX2012012960A (es) 2012-12-17
EA201291167A1 (ru) 2013-05-30
US20130172311A1 (en) 2013-07-04
ECSP12012288A (es) 2012-12-28
IL222851A0 (en) 2012-12-31
CR20120570A (es) 2013-04-22
DOP2012000284A (es) 2013-03-31
AU2011252223A1 (en) 2012-12-06
ES2462522T3 (es) 2014-05-23
TW201200510A (en) 2012-01-01
EP2569312A1 (de) 2013-03-20
TN2012000531A1 (en) 2014-04-01
WO2011141326A1 (de) 2011-11-17
CO6640218A2 (es) 2013-03-22
UY33369A (es) 2011-12-01
AR081368A1 (es) 2012-08-29
BR112012028651A2 (pt) 2016-08-09
JP5727002B2 (ja) 2015-06-03
CN103003269A (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
MA34939B1 (fr) Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
MY171300A (en) Pharmaceutical composition
MA33279B1 (fr) Compositions et procédés pour l'augmentation de la croissance des muscles
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
MX2013011314A (es) Tratamientos oftalmicos.
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201270480A1 (ru) Новые соединения
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
DOP2010000232A (es) Derivados de indazol
MX2009010407A (es) Derivados fluorados de deferiprona.
MA30090B1 (fr) Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie
EP2638910A4 (en) COMPOSITION WITH BENPROPERINE DERIVATIVES AS ACTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF ANGIOGENIC CONDITIONS